Roche's Actemra nabs 'breakthrough' tag for new use; Novartis rolls out new Cosentyx data in ankylosing spondylitis;

> Roche ($RHHBY) won the FDA's coveted "breakthrough" designation for a new use for its anti-inflammatory drug Actemra, in patients with systemic sclerosis. Release

> Novartis ($NVS) touted one-year data from its MEASURE 2 study showing that 74% of ankylosing spondylitis patients saw significant, sustained improvement with Cosentyx therapy. Release

> The National Institute for Health and Care Excellence turned down Celgene's ($CELG) psoriasis med Otezla, in contrast to the Scottish Medicines Consortium's decision in favor of the drug. Report

> Life sciences sales specialist Aktana rolled out a new product connecting its decision-making support solution to Veeva Systems' new CRM software. Release (PDF)

And Finally... Johnson & Johnson's ($JNJ) Tylenol brand ID'd Canada's most sleepless cities in a survey to help sell its sleep aids. Report


Suggested Articles

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.